Physician profile
Laurel Lawrence
NPI 1730614405
$1,548.19
in general payments reported to CMS, 2019-2025
17 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $291 · 2023: $551 · 2024: $276 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.71 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $297.50 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $249.62 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $124.60 | 2021-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.11 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $115.88 | 2023-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $115.48 | 2021-2025 | Lupkynis |
| Daiichi Sankyo INC. | $110.75 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $109.43 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $58.08 | 2021-2024 | Farxiga |
| Opko Pharmaceuticals, LLC | $47.37 | 2022 | |
| Horizon Therapeutics Plc | $46.66 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $40.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.79 | 2024 | |
| Glaxosmithkline, LLC. | $23.42 | 2023 | Benlysta |
| Novo Nordisk INC | $22.81 | 2024 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $21.16 | 2021 | |
| Kyowa Kirin, INC. | $19.94 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.